What's new

Human medicines European public assessment report (EPAR): Cejemly, sugemalimab, Date of authorisation: 24/07/2024, Revision: 4, Status: Authorised

Human medicines European public assessment report (EPAR): Cejemly, sugemalimab, Date of authorisation: 24/07/2024, Revision: 4, Status: Authorised

Apr 3, 2025 - 16:37
 0
Human medicines European public assessment report (EPAR): Cejemly, sugemalimab, Date of authorisation: 24/07/2024, Revision: 4, Status: Authorised
Human medicines European public assessment report (EPAR): Cejemly, sugemalimab, Date of authorisation: 24/07/2024, Revision: 4, Status: Authorised
Read More

Tags:

Previous Article

Novo's commercial strategy head hits the exit, prompting a slew of executive tea...

Next Article

AI chatbots boost patient engagement and reduce clinician workload, study shows

Related Posts

Human medicines European public assessment report (EPAR): Polivy, polatuzumab vedotin, Date of authorisation: 16/01/2020, Revision: 6, Status: Authorised

Human medicines European public assessment report (EPAR...

Mar 21, 2025  0

Human medicines European public assessment report (EPAR): Quofenix, delafloxacin, Date of authorisation: 16/12/2019, Revision: 9, Status: Authorised

Human medicines European public assessment report (EPAR...

Mar 5, 2025  0

EMEA-001949-PIP02-18-M04

EMEA-001949-PIP02-18-M04

Mar 14, 2025  0